梅鲁斯股票在2024年11月创下52周高位, Merus stock hit a 52-week high in November 2024 amid ongoing cancer drug trials and insider selling.

2024年11月27日, Merus(MRUS)创下52周高点96.83美元, Merus (MRUS) hit a 52-week high of $96.83 on November 27, 2024, closing at $96.77 amid a "Hold" analyst consensus and a $93.56 target price. 该股票的市场上限为73.4亿美元,仍然高于50天和200天移动平均数。 The stock, with a $7.34 billion market cap, remains above its 50-day and 200-day moving averages. 11月25日至26日,副总统哈利·舒曼(Harry Shuman)以平均95.92美元和96.10美元的价格出售了10 000股股票,将股本减少13.38%,减至11 002股,价值约106万美元。 Vice President Harry Shuman sold 10,000 shares on November 25–26 at average prices of $95.92 and $96.10, reducing his stake by 13.38% to 11,002 shares, valued at about $1.06 million. 这家总部位于荷兰的公司正在推进其双特异性抗体候选药物Zenocutuzumab (MCLA-128) 在转移性乳腺癌和抵抗割的前列腺癌的第二阶段试验,以及对Neuregulin 1-正的固体瘤的1/2阶段试验. The company, based in the Netherlands, is advancing its bispecific antibody candidate Zenocutuzumab (MCLA-128) in phase 2 trials for metastatic breast and castration-resistant prostate cancer, and phase 1/2 trials for Neuregulin 1-positive solid tumors. 机构投资者持有96.14%的股权。 Institutional investors hold 96.14% of shares.